New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
10:00 EDTDVA, TER, WBMD, R, MRO, HST, OFC, ESV, SNY, RDS.A, ITG, EVR, ADBE, BSX, CVS, SPW, RJF, GFIGOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Adobe (ADBE) upgraded to Outperform from Underperform at JMP Securities... Corporate Office Properties (OFC) upgraded to Neutral from Sell at Citigroup... DaVita (DVA) upgraded to Buy from Neutral at Nomura... Evercore Partners (EVR) upgraded to Outperform from Market Perform at Keefe Bruyette... GFI Group (GFIG) upgraded to Outperform from Market Perform at Keefe Bruyette... Host Hotels (HST) upgraded to Buy from Neutral at Citigroup... ITG (ITG) upgraded to Outperform from Market Perform at Keefe Bruyette... Marathon Oil (MRO) upgraded to Buy from Neutral at Goldman... Raymond James (RJF) upgraded to Outperform from Market Perform at Keefe Bruyette... Royal Dutch Shell (RDS.A) upgraded to Outperform from Neutral at Credit Suisse... Ryder (R) upgraded to Top Pick from Outperform at RBC Capital... SPX Corp. (SPW) upgraded to Buy from Neutral at Nomura... Sanofi (SNY) upgraded to Buy from Hold at Jefferies... WebMD (WBMD) upgraded to Market Perform from Underperform at Raymond James... CVS Caremark (CVS) upgraded to Outperform from Neutral at Macquarie... Ensco (ESV) upgraded to Buy from Hold at Jefferies... Teradyne (TER) upgraded to Outperform from Sector Perform at Pacific Crest... Boston Scientific (BSX) upgraded to Overweight from Underweight at Barclays.
News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 1, 2015
09:01 EDTSNYRegeneron and Sanofi announces Praluent Phase 3 data
Regeneron (REGN) and Sanofi (SNY) announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia patients included in the ODYSSEY clinical trial program, Praluent significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol. This analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C compared to placebo in both arms. Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.
August 31, 2015
16:09 EDTRLongbow to hold a conference
Subscribe for More Information
09:07 EDTSNYSanofi, Google Life Sciences to collaborate to improve diabetes health outcomes
Subscribe for More Information
06:35 EDTSNYAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTSNYAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
10:02 EDTROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ADP (ADP) upgraded to Outperform from Market Perform at William Blair... ASML (ASML) upgraded to Buy from Hold at Berenberg... Abercrombie & Fitch (ANF) upgraded on Hollister fundamentals at RBC Capital... Akamai (AKAM) upgraded to Outperform from Market Perform at JMP Securities... Ares Capital (ARCC) upgraded to Outperform from Market Perform at Raymond James... Banco Santander (SAN) upgraded on valuation at Deutsche Bank... CIBC (CM) upgraded to Neutral from Underperform at Credit Suisse... Canon (CAJ) upgraded to Hold from Sell at Deutsche Bank... Citi (C) upgraded to Buy from Neutral at Guggenheim... Ctrip.com (CTRP) upgraded to Buy from Hold at Stifel... El Pollo Loco (LOCO) upgraded at Stifel... Genomic Health (GHDX) upgraded to Market Perform from Underperform at Raymond James... Golar LNG (GLNG) upgraded on valuation, upcoming project completion at Stifel... Habit Restaurants (HABT) upgraded to Buy from Hold at Stifel... Helmerich & Payne (HP) upgraded to Overweight from Equal Weight at Stephens... Himax (HIMX) upgraded to Outperform from Neutral at Credit Suisse... Huntington Bancshares (HBAN) upgraded to Buy from Neutral at Guggenheim... InterContinental (IHG) upgraded to Outperform from Neutral at Credit Suisse... Knight Transportation (KNX) upgraded to Strong Buy on valuation at Raymond James... LogMeln (LOGM) upgraded to Overweight from Sector Weight at Pacific Crest... Patterson Companies (PDCO) upgraded to Overweight from Neutral at Piper Jaffray... Qunar (QUNR) upgraded on valuation, positive catalysts at Stifel... Regions Financial (RF) upgraded to Buy from Neutral at Guggenheim... Ryder (R) upgraded to Strong Buy from Outperform at Raymond James... SVB Financial (SIVB) upgraded to Buy from Neutral at DA Davidson... Seagate (STX) upgraded to Buy from Hold at Cross Research... Sinopec (SNP) upgraded to Neutral from Sell at Citi... Summit Hotel Properties (INN) upgraded to Outperform at Baird... Texas Capital (TCBI) upgraded to Buy from Neutral at DA Davidson... The Medicines Co. (MDCO) upgraded to Buy from Hold at Jefferies... U.S. Bancorp (USB) upgraded to Buy from Neutral at Guggenheim... Weatherford (WFT) upgraded to Overweight from Equal Weight at Stephens.
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
06:11 EDTRRyder upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded Ryder to Strong Buy from Outperform and maintained its $105 price target. The firm upgraded shares primarily based on valuation and said Asian concerns should not impact consumers in the U.S. to a level that will impact Ryder's businesses substantially.
August 27, 2015
19:14 EDTCVS, SNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
10:00 EDTBSXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:32 EDTCVSCVS Health enters into two new clinical affiliations
CVS Health has entered into new clinical affiliations with two health systems, St. Luke's University Health Network in Bethlehem, Pennsylvania and TriHealth in Cincinnati, Ohio. Through these clinical affiliations, CVS Health will provide prescription and visit information to the participating health care organizations.
06:12 EDTBSXBoston Scientific upgraded to Buy on valuation at Goldman
Subscribe for More Information
August 26, 2015
11:01 EDTAAgilent partners with Weill Cornell Medical College for ALS research
Subscribe for More Information
08:32 EDTCVSCVS Health to partner with telehealth providers to improve patient care
Subscribe for More Information
06:59 EDTSPWSPX Corp. to host analyst and investor meeting
Subscribe for More Information
August 25, 2015
18:11 EDTESVTranocean tanks after proposing dividend cancellations, peers follow
Subscribe for More Information
16:01 EDTCVSTarget sees $550M pretax gain after closing CVS transaction
Subscribe for More Information
09:59 EDTTEROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:09 EDTTERTeradyne upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
August 24, 2015
16:32 EDTBSXBoston Scientific announces CE Mark for MRI labeling for ICD, CRT-D systems
Boston Scientific has received CE Mark on magnetic resonance imaging conditional labeling for the current family of EL and MINI implantable cardioverter defibrillator and the X4 cardiac resynchronization therapy defibrillator systems. This revised labeling ensures that future patients and those already implanted with these systems are able to undergo MRI scans if indicated.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use